Post-COVID-19 pulmonary sequla : longterm follow up and management
Though it has been 8 months since the beginning of COVID-19 pandemic, number of cases and deaths are still seriously increasing. We still don't have enough evidence about the prognosis of patients who had COVID-19 pneumonia. In long term follow up we wonder if they will have rapid FVC decline, widespread fibrosis in computed tomography, loss in quality of life or increased mortality that we experience in idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonia or autoimmune interstitial lung diseases. However, in elderly patients less severe dysfunction or non-progressive-fibrosis can cause morbidity and mortality. Therefore, if we consider millions of people who are affected by COVID-19, even a rare complication can cause serious health problem in social scale. Because of the importance of this issue randomized controlled trials should be rapidly planned on post-COVID fibrosis, COVID associated thrombosis, risk factors, prevention and treatment (1). In this review, the frequency, clinical importance, prevention and treatment of possible long-term sequels of COVID-19 pneumonia (pulmonary fibrosis, pulmonary embolism and pulmonary hypertension) will be discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Tuberkuloz ve toraks - 68(2020), 4 vom: 01. Dez., Seite 419-429 |
| Sprache: |
Türkisch |
|---|
| Weiterer Titel: |
COVID-19 sonrası akciğer sekelleri: uzun dönem takip ve tedavi |
|---|
| Beteiligte Personen: |
Türktaş, Haluk [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.01.2021 Date Revised 22.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5578/tt.70353 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320119416 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320119416 | ||
| 003 | DE-627 | ||
| 005 | 20231225172911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||tur c | ||
| 024 | 7 | |a 10.5578/tt.70353 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1067.xml |
| 035 | |a (DE-627)NLM320119416 | ||
| 035 | |a (NLM)33448739 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a tur | ||
| 100 | 1 | |a Türktaş, Haluk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-COVID-19 pulmonary sequla |b longterm follow up and management |
| 246 | 3 | 3 | |a COVID-19 sonrası akciğer sekelleri: uzun dönem takip ve tedavi |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2021 | ||
| 500 | |a Date Revised 22.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Though it has been 8 months since the beginning of COVID-19 pandemic, number of cases and deaths are still seriously increasing. We still don't have enough evidence about the prognosis of patients who had COVID-19 pneumonia. In long term follow up we wonder if they will have rapid FVC decline, widespread fibrosis in computed tomography, loss in quality of life or increased mortality that we experience in idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonia or autoimmune interstitial lung diseases. However, in elderly patients less severe dysfunction or non-progressive-fibrosis can cause morbidity and mortality. Therefore, if we consider millions of people who are affected by COVID-19, even a rare complication can cause serious health problem in social scale. Because of the importance of this issue randomized controlled trials should be rapidly planned on post-COVID fibrosis, COVID associated thrombosis, risk factors, prevention and treatment (1). In this review, the frequency, clinical importance, prevention and treatment of possible long-term sequels of COVID-19 pneumonia (pulmonary fibrosis, pulmonary embolism and pulmonary hypertension) will be discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Oğuzülgen, İ Kıvılcım |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberkuloz ve toraks |d 2003 |g 68(2020), 4 vom: 01. Dez., Seite 419-429 |w (DE-627)NLM147934990 |x 0494-1373 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2020 |g number:4 |g day:01 |g month:12 |g pages:419-429 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5578/tt.70353 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2020 |e 4 |b 01 |c 12 |h 419-429 | ||